||University of Birmingham
||European Union FP7
||Clinical Trial of an Investigational Medical Product
|UKCRN Study ID: (if applicable)
|Open to new sites?
|Recruitment start date:
|Anticipated Recruitment end date
|CRCTU Trial Management Team:
||Children's Cancer Trials Team
|Trial E-mail Address:
rEECur is a randomised study to compare four chemotherapy regimens to see which is the best at treating recurrent or refractory Ewing sarcoma. Ewing sarcoma is rare and running a study such as this requires funding and collaboration across many different treatment centres and countries. The logistics behind running such a study are not trivial and as a result rEECur is the first study to directly compare different chemotherapy regimens in this disease setting. Most doctors treat recurrent and refractory Ewing sarcoma with chemotherapy. However, although several chemotherapy regimens are available to treat this disease, we do not know which is the best regimen to use. We are primarily interested in finding out which regimen is most effective at making tumour deposits shrink and, in the longer term, at curing the disease or providing prolonged disease control. We will also determine which regimen has the most side effects, which is associated with the most time spent in hospital and which has the greatest effect on quality of life.
The results will help us to know which chemotherapy regimen is the best to use for patients with this disease. It will also allow us to inform patients about the relative burden of side effects associated with each regimen, allowing individual patients and/or parents to make an informed choice about how to be treated.
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.